Table 3 Associations of ESR1 fusions with clinical parameters in prognostic clinical cohort
From: The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
LNN ESR + Prognostic cohort | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Parameters | n | at least one ESR1-CCDC170 (exon 2 to 8) fusion | P-value | ESR1-CCDC170 (exon 2) fusion | P-value | ESR1-CCDC170 (exon 8) fusion | P-value | ESR1-AKAP12 | P-value | |||||
n | % | n | % | n | % | n | % | |||||||
All patients | 279 | 70 | 25.1% | 33 | 11.8% | 39 | 14.0% | 5 | 1.8% | |||||
Age at primary surgery | ||||||||||||||
≤ 40 years | 29 | 6 | 20.7% | 0.001 | 4 | 13.8% | 0.38 | 4 | 13.8% | 0.26 | 1 | 3.4% | 0.27 | |
41–50 years | 81 | 11 | 13.6% | 5 | 6.2% | 5 | 6.2% | 0 | 0.0% | |||||
51–70 years | 125 | 36 | 28.8% | 16 | 12.8% | 21 | 16.8% | 3 | 2.4% | |||||
> 70 years | 44 | 17 | 38.6% | 8 | 18.2% | 9 | 20.5% | 1 | 2.3% | |||||
Menopausal status | ||||||||||||||
Premenopausal | 120 | 19 | 15.8% | 0.002 | 10 | 8.3% | 0.12 | 11 | 9.2% | 0.044 | 1 | 0.8% | 0.29 | |
Postmenopausal | 159 | 51 | 32.1% | 23 | 14.5% | 28 | 17.6% | 4 | 2.5% | |||||
Surgery type | ||||||||||||||
Lumpectomy | 178 | 44 | 24.7% | 0.85 | 19 | 10.7% | 0.43 | 25 | 14.0% | 0.97 | 4 | 2.2% | 0.45 | |
Ablation | 101 | 26 | 25.7% | 14 | 13.9% | 14 | 13.9% | 1 | 1.0% | |||||
Radiotherapy | ||||||||||||||
No | 84 | 24 | 28.6% | 0.38 | 14 | 16.7% | 0.10 | 12 | 14.3% | 0.92 | 1 | 1.2% | 0.62 | |
Yes | 195 | 46 | 23.6% | 19 | 9.7% | 27 | 13.8% | 4 | 2.1% | |||||
Nodal status | ||||||||||||||
No lymph nodes | 279 | 70 | 25.1% | 33 | 11.8% | 39 | 14.0% | 5 | 1.8% | |||||
Positive lymph nodes | 0 | 0 | 0 | 0 | 0 | |||||||||
Tumor outside lymph nodes | 0 | 0 | 0 | 0 | 0 | |||||||||
Pathological Tumor classification | ||||||||||||||
pT1 | 151 | 34 | 22.5% | 0.28 | 17 | 11.3% | 0.61 | 16 | 10.6% | 0.08 | 2 | 1.3% | 0.1 | |
pT2 + unknown | 119 | 32 | 26.9% | 14 | 11.8% | 20 | 16.8% | 2 | 1.7% | |||||
pT3 + pT4 | 9 | 4 | 44.4% | 2 | 22.2% | 3 | 33.3% | 1 | 11.1% | |||||
Tumor grade | ||||||||||||||
Poor | 131 | 36 | 27.5% | 0.60 | 21 | 16.0% | 0.06 | 21 | 16.0% | 0.56 | 3 | 2.3% | 0.84 | |
Unknown | 81 | 20 | 24.7% | 9 | 11.1% | 11 | 13.6% | 1 | 1.2% | |||||
Moderate/Good | 67 | 14 | 20.9% | 3 | 4.5% | 7 | 10.4% | 1 | 1.5% | |||||
Tumor cell content | ||||||||||||||
30–49% | 31 | 9 | 29.0% | 0.82 | 6 | 19.4% | 0.38 | 4 | 12.9% | 0.86 | 1 | 3.2% | 0.81 | |
50–70% | 69 | 16 | 23.2% | 7 | 10.1% | 11 | 15.9% | 1 | 1.4% | |||||
> 70% | 179 | 45 | 25.1% | 20 | 11.2% | 24 | 13.4% | 3 | 1.7% | |||||
Hormone/ growth factor status (RT-qPCR) | ||||||||||||||
ESR1 negative | 0 | 0 | 0 | 0 | 0 | |||||||||
ESR1 positive | 279 | 70 | 25.1% | 33 | 11.8% | 39 | 14.0% | 5 | 1.8% | |||||
PR negative | 62 | 16 | 25.8% | 0.88 | 9 | 14.5% | 0.46 | 8 | 12.9% | 0.78 | 2 | 3.2% | 0.93 | |
PR positive | 217 | 54 | 24.9% | 24 | 11.1% | 31 | 14.3% | 3 | 1.4% | |||||
HER2 non-amplified | 233 | 62 | 26.6% | 0.15 | 29 | 12.4% | 0.30 | 34 | 14.6% | 0.61 | 4 | 1.7% | 0.78 | |
HER2 amplified | 43 | 7 | 16.3% | 3 | 7.0% | 5 | 11.6% | 1 | 2.3% | |||||
CCDC170 negative | 26 | 4 | 15.4% | 0.23 | 2 | 7.7% | 0.49 | 3 | 11.5% | 0.70 | 0 | 0.0% | 0.47 | |
CCDC170 positive | 252 | 66 | 26.2% | 31 | 12.3% | 36 | 14.3% | 5 | 2.0% | |||||
Disease-free interval | ||||||||||||||
≤ 1 year disease-free | 20 | 7 | 35.0% | 0.011 | 2 | 10.0% | 0.08 | 4 | 20.0% | 0.006 | 0 | 0.0% | 0.57 | |
1–3 years disease-free | 71 | 18 | 25.4% | 10 | 14.1% | 14 | 19.7% | 2 | 2.8% | |||||
> 3 years disease-free | 188 | 45 | 23.9% | 21 | 11.2% | 21 | 11.2% | 3 | 1.6% | |||||
Adjuvant endocrine therapy | ||||||||||||||
No | 279 | 66 | 23.7% | 33 | 11.8% | 39 | 14.0% | 5 | 1.8% | |||||
Yes | 0 | 0 | 0 | 0 | 0 | |||||||||
Adjuvant chemotherapy | ||||||||||||||
No | 279 | 66 | 23.7% | 33 | 11.8% | 39 | 14.0% | 5 | 1.8% | |||||
Yes | 0 | 0 | 0 | 0 | 0 | |||||||||